Randomized, Placebo-Controlled, Crossover Trial of Memantine for Cognitive Changes with Corticosteroid Therapy


      In animal models, corticosteroids are associated with changes in hippocampal structure and functioning that are prevented by glutamate release inhibitors or N-methyl-D-aspartate (NMDA) receptor antagonists. Cushing's disease and prescription corticosteroid administration are also associated with memory impairment and hippocampal atrophy. Use of NMDA receptor antagonists to attenuate corticosteroid effects in humans has not been investigated. We examine the NMDA receptor antagonist memantine in patients receiving corticosteroids.


      Twenty outpatients receiving long-term oral corticosteroid therapy were randomized to 8 weeks of memantine (maximum dose 20 mg/day) and 8 weeks of placebo in a double-blind fashion, with a 4-week washout period between courses. Declarative memory was assessed with the Hopkins Verbal Learning Test (HVLT) and mood with the Hamilton Rating Scale for Depression and Young Mania Rating Scale. Changes in outcome measures were compared during memantine and placebo exposure.


      Seventeen participants completed both treatment phases and were used in the analysis. Significant improvement (p < .05) in total and delayed recall on the HVLT was observed with memantine as compared with placebo. No significant changes in mood were observed.


      Memantine therapy was associated with improvement in declarative memory but not mood in patients receiving prescription corticosteroids.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Brown E.S.
        • Rush A.J.
        • McEwen B.S.
        Hippocampal remodeling and damage by corticosteroids: Implications for mood disorders.
        Neuropsychopharmacology. 1999; 21: 474-484
        • Sapolsky R.M.
        The possibility of neurotoxicity in the hippocampus in major depression: A primer on neuron death.
        Biol Psychiatry. 2000; 48: 755-765
        • Starkman M.N.
        • Gebarski S.S.
        • Berent S.
        • Schteingart D.E.
        Hippocampal formation volume, memory dysfunction, and cortisol levels in patients with Cushing's syndrome.
        Biol Psychiatry. 1992; 32: 756-765
        • Starkman M.N.
        • Giordani B.
        • Berent S.
        • Schork M.A.
        • Schteingart D.E.
        Elevated cortisol levels in Cushing's disease are associated with cognitive decrements.
        Psychosom Med. 2001; 63: 985-993
        • Brown E.S.
        • Woolston J.
        • Frol A.
        • Bobadilla L.
        • Khan D.A.
        • Hanczyc M.
        • et al.
        Hippocampal volume, spectroscopy, cognition, and mood in patients receiving corticosteroid therapy.
        Biol Psychiatry. 2004; 55: 538-545
        • Moghaddam B.
        • Bolinao M.L.
        • Stein-Behrens B.
        • Sapolsky R.
        Glucocorticoids mediate the stress-induced extracellular accumulation of glutamate.
        Brain Res. 1994; 655: 251-254
        • Stein-Behrens B.A.
        • Lin W.J.
        • Sapolsky R.M.
        Physiological elevations of glucocorticoids potentiate glutamate accumulation in the hippocampus.
        J Neurochem. 1994; 63: 596-602
        • Magarinos A.M.
        • Deslandes A.
        • McEwen B.S.
        Effects of antidepressants and benzodiazepine treatments on the dendritic structure of CA3 pyramidal neurons after chronic stress.
        Eur J Pharmacol. 1999; 371: 113-122
        • Magarinos A.M.
        • McEwen B.S.
        Stress-induced atrophy of apical dendrites of hippocampal CA3c neurons: Involvement of glucocorticoid secretion and excitatory amino acid receptors.
        Neuroscience. 1995; 69: 89-98
        • Starkman M.N.
        • Giordani B.
        • Gebarski S.S.
        • Schteingart D.E.
        Improvement in learning associated with increase in hippocampal formation volume.
        Biol Psychiatry. 2003; 53: 233-238
        • Brown E.S.
        • Frol A.
        • Bobadilla L.
        • Nejtek V.A.
        • Perantie D.C.
        • Dhillon H.
        Effect of lamotrigine on mood and cognition in patients receiving chronic exogenous corticosteroids.
        Psychosomatics. 2003; 44: 204-208
        • Brown E.S.
        • Wolfshohl J.
        • Shad M.U.
        • Vazquez M.
        • Osuji I.J.
        Attenuation of the effects of corticosteroids on declarative memory with lamotrigine.
        Neuropsychopharmacology. 2008; ([published online ahead of print November 14])
        • Parsons C.G.
        • Stoffler A.
        • Danysz W.
        Memantine: A NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system—too little activation is bad, too much is even worse.
        Neuropharmacology. 2007; 53: 699-723
        • Tariot P.N.
        • Farlow M.R.
        • Grossberg G.T.
        • Graham S.M.
        • McDonald S.
        • Gergel I.
        • Memantine Study Group
        Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial.
        JAMA. 2004; 291: 317-324
        • Brandt J.
        The Hopkins Verbal Learning Test: Development of a new memory test with six equivalent forms.
        Clin Neuropsychol. 1991; 5: 125-142
        • Hamilton M.
        A rating scale for depression.
        J Neurol Neurosurg Psychiatry. 1960; 23: 56-62
        • Young R.C.
        • Biggs J.T.
        • Ziegler V.E.
        • Meyer D.A.
        A rating scale for mania: Reliability, validity and sensitivity.
        Br J Psychiatry. 1978; 133: 429-435
        • Potter J.M.
        • McWhinney B.C.
        • Sampson L.
        • Hickman P.E.
        Area-under-the-curve monitoring of prednisolone for dose optimization in a stable renal transplant population.
        Ther Drug Monit. 2004; 26: 408-414
        • Brown E.S.
        • Suppes T.
        • Khan D.A.
        • Carmody III, T.J.
        Mood changes during prednisone bursts in outpatients with asthma.
        J Clin Psychopharmacol. 2002; 22: 55-61